CGRP-receptor antagonism in migraine treatment.
Edvinsson
Lars
L
Department of Internal Medicine, Lund University, University Hospital, 221 85 Lund, Sweden. lars.edvinsson@med.lu.se
D000818:Animals; D001381:Azepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015740:Calcitonin Gene-Related Peptide / Q000502:physiology*; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism; D023303:Oxazolidinones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D014363:Tryptamines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
D001381:Azepines; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D007093:Imidazoles; D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; C525458:telcagepant; D015740:Calcitonin Gene-Related Peptide